



## Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

05-21-2026 at 5:30 PM EDT

*Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors*

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026.

### Poster Presentation

**Title:** [Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual  \$\alpha\_v\beta\_3\$  / \$\alpha\_v\beta\_1\$  Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors](#)

**Presenter:** Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center

**Session:** Developmental Therapeutics – Immunotherapy

**Date:** Saturday, May 30, 2026, 1:30 – 4:30 p.m. Central Time

**Location:** Hall A, Poster 467b

### FORTIFY - PLN-101095 Phase 1b Indication Expansion Trial

PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial ([NCT06270706](#)) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy.

### About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant's lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of  $\alpha_v\beta_3$  and  $\alpha_v\beta_1$  integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant's preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells.

For additional information on Pliant, visit [www.PliantRx.com](http://www.PliantRx.com) and follow us on [X](#), [LinkedIn](#) and [Facebook](#).

### Investor and Media Contact:

Christopher Keenan

Vice President, Investor Relations and Corporate Communications

Pliant Therapeutics, Inc.

[ir@pliantrx.com](mailto:ir@pliantrx.com)